SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

ClinicalTrials.gov ID: NCT03669614

Public ClinicalTrials.gov record NCT03669614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects

Study identification

NCT ID: NCT03669614
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Enrollment: 102 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

Inhaled AR-501 Drug
Inhaled Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 49 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 6, 2018
Primary completion: Jun 30, 2023
Completion: Jun 30, 2023
Last update posted: Mar 8, 2023

2018 – 2023

United States locations

U.S. sites: 25
U.S. states: 19
U.S. cities: 25

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85724	Recruiting
Research Site	Long Beach	California	90806	Recruiting
Research Site	Denver	Colorado	80206	Recruiting
Research Site	Gainesville	Florida	32610	Recruiting
Research Site	Hollywood	Florida	33021	Recruiting
Research Site	Miami	Florida	33136	Recruiting
Research Site	Orlando	Florida	32803	Recruiting
Research Site	Tampa	Florida	33606	Recruiting
Research Site	Chicago	Illinois	60093	Recruiting
Research Site	Iowa City	Iowa	55242	Recruiting
Research Site	Overland Park	Kansas	66212	Completed
Research Site	Louisville	Kentucky	40202	Recruiting
Research Site	Portland	Maine	04102	Recruiting
Research Site	Baltimore	Maryland	21204	Recruiting
Research Site	Detroit	Michigan	48201	Recruiting
Research Site	Omaha	Nebraska	68198	Recruiting
Research Site	New York	New York	10532	Recruiting
Research Site	Cleveland	Ohio	44106	Recruiting
Research Site	Columbus	Ohio	43205	Recruiting
Research Site	Oklahoma City	Oklahoma	73104	Recruiting
Research Site	Philadelphia	Pennsylvania	19104	Recruiting
Research Site	Tyler	Texas	75708	Recruiting
Research Site	Salt Lake City	Utah	84132	Recruiting
Research Site	Seattle	Washington	98195	Recruiting
Research Site	Spokane	Washington	99204	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03669614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 8, 2023 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03669614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →